Nona Biosciences Appoints Josh Xiao as New CSO
CAMBRIDGE, Mass., May 6, 2026 Nona Biosciences, a global biotechnology company specializing in biotherapeutic discovery and AI-driven drug development...
Phase II trial
Advertisement
Bayer to Acquire Perfuse Therapeutics in $2.45B Deal
BERLIN, Germany, and SAN FRANCISCO, Calif., May 6, 2026 Bayer has announced an agreement to fully acquire Perfuse Therapeutics...
FDA Clears IND for CS2009 Trispecific Antibody Trial
SUZHOU, China, Feb. 15, 2026 — CStone Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Investigational...
AK3280 Anti-Fibrotic Drug Cleared for U.S. Phase II Trial
SHANGHAI, Feb. 12, 2026 — AGCO Biomedical Technology Co., Ltd. announced that the U.S. Food and Drug Administration (FDA)...
Apecotrep Shows 40% Proteinuria Reduction in Phase II FSGS Trial
Ingelheim, Germany | January 29, 2026 — Boehringer Ingelheim announced positive results from a 12-week Phase II clinical trial...
Advertisements
FDA Clears Allogeneic CAR-T MT027 for Phase II Glioblastoma
December 21, 2025 | Beijing, China — T-MAXIMUM Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has...
Ipsen Halts Phase II FALKON Trial in Ultra-Rare FOP
Paris, France, December 19, 2025 — Ipsen, a global biopharmaceutical company, announced an update on its pivotal Phase II...
Tiakis Advances Tiprelestat into Phase II for Pulmonary Hypertension
Kiel, Germany, December 2, 2025 — Tiakis Biotech has announced that it has successfully completed the required preclinical data...
CardiolRx Phase II Trial Shows Structural Heart Recovery in Myocarditis
Toronto, December 1, 2025 — New clinical data from the Phase II ARCHER trial reveal that CardiolRx™, Cardiol Therapeutics’...
FluoGuide’s Q3 2025 Report Underscores Regulatory Momentum and Clinical Progress
KØBENHAVN, DK — November 27, 2025. FluoGuide A/S has released its Q3 2025 interim report, outlining a quarter marked...
Advertisement
